Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Bartram

Showing results (281-290 of 317) with videos related to

Pageof 32
Sort By:
BMC Cancer|December 17, 2009
Nuclear receptor coregulator SNP discovery and impact on breast cancer riskRyan J Hartmaier, Sandrine Tchatchou, Alexandra S Richter, et al.
Blood|July 2, 2011
Late MRD response determines relapse risk overall and in subsets of childhood T-cell ALL: results of the AIEOP-BFM-ALL 2000 studyMartin Schrappe, Maria Grazia Valsecchi, Claus R Bartram, et al.
BMC Cancer|March 9, 2018
Prevalence of pathogenic BRCA1/2 germline mutations among 802 women with unilateral triple-negative breast cancer without family cancer historyChristoph Engel, Kerstin Rhiem, Eric Hahnen, et al.
Diabetes|July 28, 2005
Carnosine as a protective factor in diabetic nephropathy: association with a leucine repeat of the carnosinase gene CNDP1Bart Janssen, Daniela Hohenadel, Paul Brinkkoetter, et al.
Blood|February 16, 2010
Molecular response to treatment redefines all prognostic factors in children and adolescents with B-cell precursor acute lymphoblastic leukemia: results in 3184 patients of the AIEOP-BFM ALL 2000 studyValentino Conter, Claus R Bartram, Maria Grazia Valsecchi, et al.
Blood|February 19, 2016
Dexamethasone vs prednisone in induction treatment of pediatric ALL: results of the randomized trial AIEOP-BFM ALL 2000Anja Möricke, Martin Zimmermann, Maria Grazia Valsecchi, et al.
Human Mutation|October 16, 2009
Identification of a DMBT1 polymorphism associated with increased breast cancer risk and decreased promoter activitySandrine Tchatchou, Angela Riedel, Stefan Lyer, et al.
Lancet (London, England)|December 16, 1998
Prognostic value of minimal residual disease in acute lymphoblastic leukaemia in childhoodJ J van Dongen, T Seriu, E R Panzer-Grümayer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 18, 2017
Reduced-Intensity Delayed Intensification in Standard-Risk Pediatric Acute Lymphoblastic Leukemia Defined by Undetectable Minimal Residual Disease: Results of an International Randomized Trial (AIEOP-BFM ALL 2000)Martin Schrappe, Kirsten Bleckmann, Martin Zimmermann, et al.
Scientific Reports|October 15, 2015
The 9p21.3 risk of childhood acute lymphoblastic leukaemia is explained by a rare high-impact variant in CDKN2AJayaram Vijayakrishnan, Marc Henrion, Anthony V Moorman, et al.
Pageof 32

Showing results (281-290 of 317) with videos related to

Sort By:
Pageof 32
BMC Cancer|December 17, 2009
Nuclear receptor coregulator SNP discovery and impact on breast cancer riskRyan J Hartmaier, Sandrine Tchatchou, Alexandra S Richter, et al.
Blood|July 2, 2011
Late MRD response determines relapse risk overall and in subsets of childhood T-cell ALL: results of the AIEOP-BFM-ALL 2000 studyMartin Schrappe, Maria Grazia Valsecchi, Claus R Bartram, et al.
BMC Cancer|March 9, 2018
Prevalence of pathogenic BRCA1/2 germline mutations among 802 women with unilateral triple-negative breast cancer without family cancer historyChristoph Engel, Kerstin Rhiem, Eric Hahnen, et al.
Diabetes|July 28, 2005
Carnosine as a protective factor in diabetic nephropathy: association with a leucine repeat of the carnosinase gene CNDP1Bart Janssen, Daniela Hohenadel, Paul Brinkkoetter, et al.
Blood|February 16, 2010
Molecular response to treatment redefines all prognostic factors in children and adolescents with B-cell precursor acute lymphoblastic leukemia: results in 3184 patients of the AIEOP-BFM ALL 2000 studyValentino Conter, Claus R Bartram, Maria Grazia Valsecchi, et al.
Blood|February 19, 2016
Dexamethasone vs prednisone in induction treatment of pediatric ALL: results of the randomized trial AIEOP-BFM ALL 2000Anja Möricke, Martin Zimmermann, Maria Grazia Valsecchi, et al.
Human Mutation|October 16, 2009
Identification of a DMBT1 polymorphism associated with increased breast cancer risk and decreased promoter activitySandrine Tchatchou, Angela Riedel, Stefan Lyer, et al.
Lancet (London, England)|December 16, 1998
Prognostic value of minimal residual disease in acute lymphoblastic leukaemia in childhoodJ J van Dongen, T Seriu, E R Panzer-Grümayer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 18, 2017
Reduced-Intensity Delayed Intensification in Standard-Risk Pediatric Acute Lymphoblastic Leukemia Defined by Undetectable Minimal Residual Disease: Results of an International Randomized Trial (AIEOP-BFM ALL 2000)Martin Schrappe, Kirsten Bleckmann, Martin Zimmermann, et al.
Scientific Reports|October 15, 2015
The 9p21.3 risk of childhood acute lymphoblastic leukaemia is explained by a rare high-impact variant in CDKN2AJayaram Vijayakrishnan, Marc Henrion, Anthony V Moorman, et al.
Pageof 32